EUVIMEDOpdag EUVIMED
Kohortenstudie

Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT ‐2 Inhibitors: A Nationwide Population Cohort Study

Shih-Ting Huang, Pei-Jane Bair, Shih-Sheng Chang, Yu-Nong Kao, San-Ni Chen, I-Kang Wang, Chih-Wei Chiu, Chi-Tzung Chang, Ying-Hsiu Shih, Chi-Yuan Li, Tung-Min Yu iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3074 ↗

At a glance

Kohortenstudie in Clinical Pharmacology & Therapeutics, 2024. Written by Shih-Ting Huang and 10 co-authors. Institution: Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Diabetic Retinopathy, Dipeptidyl-Peptidase IV Inhibitors. Cited 10 times so far (Crossref); 24 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Diabetic retinopathy (DR) accounts for 80% of cases of vision loss in patients with type 2 diabetes mellitus (T2DM). Interventional treatments are only indicated in advanced DR and are ineffective in some patients. Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are used to attenuate T2DM‐associated cardiovascular complications. We conducted the cohort study to investigate the effect of SGLT2is on DR development. Data (May 2016–December 2018) obtained from the Taiwan National Health Insurance Research Database were analyzed in this nationwide retrospective cohort study. After propensity score matching, a total of 31,764 patients receiving SGLT2is and another 31,764 patients receiving dipeptidyl peptidase 4 inhibitors (DPP4is) were included in this study. Multiple Cox proportional‐hazards regression models were used to evaluate DR risk. Overall DR incidence among SGLT2i or DPP4i users was 10.9 or 15.6 per 10,000 patient‐years, respectively. After covariate adjustment, DR (both early and late stage) risk was substantially lower in SGLT2i users (adjusted hazard ratio: 0.68, 95% confidence interval: 0.6–0.78) than in DPP4i users. DR risk appears to be considerably lower in SGLT2i users than in DPP4i users. Glycemic control measurement with HbA1C level was unavailable in this claim database.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDiabetic RetinopathyDipeptidyl-Peptidase IV InhibitorsHumansCohort StudiesRetrospective StudiesHypoglycemic Agents

Substances

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Authors and institutions

  • Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
  • School of Medicine, China Medical University, Taichung, Taiwan.
  • Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan.
  • Division of Cardiovascular Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan.

ORCID profiles: Tung-Min Yu

Cite

APA

Huang, S. T., Bair, P. J., Chang, S. S., Kao, Y. N., Chen, S. N., Wang, I. K., Chiu, C. W., Chang, C. T., Shih, Y. H., Li, C. Y., & Yu, T. M. (2024). Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT ‐2 Inhibitors: A Nationwide Population Cohort Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3074

Vancouver

Huang ST, Bair PJ, Chang SS, Kao YN, Chen SN, Wang IK, et al. Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT ‐2 Inhibitors: A Nationwide Population Cohort Study. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3074

BibTeX
@article{Huang2024,
  author = {Huang, Shih-Ting and Bair, Pei-Jane and Chang, Shih-Sheng and Kao, Yu-Nong and Chen, San-Ni and Wang, I-Kang and Chiu, Chih-Wei and Chang, Chi-Tzung and Shih, Ying-Hsiu and Li, Chi-Yuan and Yu, Tung-Min},
  title = {Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT ‐2 Inhibitors: A Nationwide Population Cohort Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3074}
}
Start for free →